Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?

Authors
Floiras, JL Hacene, K Turpin, F Spyratos, F
Citation
Jl. Floiras et al., Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?, INT J B MAR, 15(2), 2000, pp. 135-138
Citations number
7
Categorie Soggetti
Oncology
Journal title
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
ISSN journal
03936155 → ACNP
Volume
15
Issue
2
Year of publication
2000
Pages
135 - 138
Database
ISI
SICI code
0393-6155(200004/06)15:2<135:IATRIP>2.0.ZU;2-Z
Abstract
The impact of ER levels on the response to tamoxifen was evaluated in 1,623 postmenopausal primary breast cancer patients treated at our center (media n follow-up 8.2 years). In patients receiving adjuvant tamoxifen a signific antly longer disease-free survival (DFS) was observed when ER levels were e levated (p < 0.00001). Very high ER (>424 fmol/mg protein) appeared to be d etrimental in node-negative patients not treated with tamoxifen.